Cleerly and Cardiac Care Alliance Partner to Enhance Heart Disease Detection with AI-Powered Imaging Technology

Cleerly, a pioneer in cardiovascular imaging, and Cardiac Care Alliance, a leader in value-based cardiovascular care, have announced a strategic partnership aimed at enhancing cardiac care delivery and optimizing appropriate medical procedures. This collaboration will integrate Cleerly’s AI-powered coronary artery assessment technology with Cardiac Care Alliance's extensive network of cardiologists and healthcare providers. The partnership will roll out with cardiology practices in Texas before expanding nationwide. By using Cleerly’s noninvasive Artificial Intelligence–Quantitative Coronary Tomography (AI-QCT) technology, the goal is to ensure that symptomatic patients receive accurate assessments prior to potentially unnecessary and expensive cardiac catheterization procedures. This approach is designed to direct the right patients to the catheterization lab while sparing others from invasive testing, thereby improving clinical outcomes and reducing healthcare costs. Cardiac Care Alliance works to improve access to care and reduce unnecessary spending by collaborating with cardiologists, primary care providers, patients, health systems, and payers. Their value-based model emphasizes proactive, personalized, and patient-centered care. Cleerly’s AI-QCT technology, which is FDA-cleared, provides a comprehensive and standardized assessment of coronary artery disease using advanced noninvasive CT imaging. This technology has been validated through extensive studies, demonstrating superior accuracy compared to traditional methods, even surpassing expert physician readings. According to Dr. Prakash Patel, CEO and Chairman of Cardiac Care Alliance, this partnership aligns with their mission to deliver clinically effective and economically sustainable solutions. Cardiovascular disease is currently the most costly chronic condition in the U.S., accounting for about $233 billion annually or roughly 11% of total healthcare expenditures. The aging population is expected to exacerbate these costs, with projections indicating they could rise to over $1 trillion by 2035. By providing early and precise detection of heart disease, the partnership aims to improve patient outcomes and reduce financial burdens. Dr. James Min, founder and CEO of Cleerly, underscores the significance of this partnership as Cleerly's first step into value-based care. The company’s mission is to eliminate heart attacks by establishing a new standard of care through advanced imaging and AI. Dr. Min highlights that early detection and intervention can significantly reduce the risk of severe cardiovascular events and save lives. Given that hospital readmissions for cardiac conditions are among the most common and costly within Medicare, Cleerly's technology offers a promising solution to address these challenges. Key Developments and Insights Partnership Overview: Companies Involved: Cleerly and Cardiac Care Alliance Objective: To enhance cardiovascular care delivery and optimize appropriate medical procedures. Technology Integration: Cleerly's AI-QCT technology will be integrated into Cardiac Care Alliance’s network. Initial Rollout: Starting with cardiology practices in Texas, with plans for broader implementation. Benefits: Noninvasive Assessment: Provides accurate detection of coronary artery disease without invasive procedures. Cost Reduction: Reduces unnecessary testing and associated costs, improving economic sustainability. Patient Outcomes: Enhances clinical decisions, leading to better patient outcomes. Validation: Studies: Multiple studies have shown that Cleerly’s AI-QCT technology outperforms traditional methods and even expert physician readings. FDA Clearance: Cleerly’s solutions are approved by the FDA, ensuring regulatory compliance and safety. Financial Impact: Current Costs: Cardiovascular disease costs the U.S. healthcare system $233 billion annually. Future Projections: Costs could soar to $1 trillion by 2035 due to an aging population. Readmissions: Hospital readmissions for cardiac conditions are frequent and costly under Medicare. Evaluation by Industry Insiders Industry experts view this collaboration as a significant step forward in the integration of AI into cardiac care. The partnership leverages the strengths of both companies—Cleerly’s cutting-edge imaging technology and Cardiac Care Alliance’s extensive network and value-based care expertise—to tackle the growing financial and clinical challenges posed by cardiovascular disease. This approach not only promises to improve diagnostic accuracy and patient outcomes but also has the potential to drive substantial cost savings in the healthcare sector. Cleerly’s AI-powered technology has already garnered attention for its ability to detect coronary artery disease with high precision, making it a valuable tool in preventing heart attacks and other severe cardiac events. Meanwhile, Cardiac Care Alliance’s focus on delivering cost-effective and high-quality care aligns perfectly with the goals of this partnership. Together, they are positioned to make a meaningful impact on the way cardiac care is delivered and managed in the U.S. Company Profiles Cleerly: - Mission: To eliminate heart attacks by setting a new standard of care for heart disease. - Technology: FDA-cleared AI-QCT technology for noninvasive coronary artery assessment. - Scientific Foundation: Based on millions of images from over 40,000 patients. - Team: Comprised of world-class clinical and technical experts. Cardiac Care Alliance: - Model: Innovative, integrated, and partnership-driven approach to cardiovascular care. - Focus: Improving access, patient outcomes, and cost optimization. - Network: Extends to cardiologists, primary care providers, health systems, payers, and patients. - Commitment: To deliver proactive, personalized, and patient-centered care. This partnership represents a promising synergy between advanced technology and comprehensive care management, poised to revolutionize the field of cardiovascular disease detection and treatment.